1. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. 2010; Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 7:e1000267. DOI:
10.1371/journal.pmed.1000267. PMID:
20422030. PMCID:
PMC2857873.
Article
2. Jang JY, Kang MJ, Heo JS, Choi SH, Choi DW, Park SJ, et al. 2014; A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg. 259:656–664. DOI:
10.1097/SLA.0000000000000384. PMID:
24368638.
Article
3. Versteijne E, Vogel JA, Besselink MG, Busch ORC, Wilmink JW, Daams JG, et al. 2018; Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. Br J Surg. 105:946–958. DOI:
10.1002/bjs.10870. PMID:
29708592. PMCID:
PMC6033157.
Article
4. Papalezova KT, Tyler DS, Blazer DG 3rd, Clary BM, Czito BG, Hurwitz HI, et al. 2012; Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer? J Surg Oncol. 106:111–118. DOI:
10.1002/jso.23044. PMID:
22311829.
Article
5. Bakens MJ, van der Geest LG, van Putten M, van Laarhoven HW, Creemers GJ, Besselink MG, et al. 2016; The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis. Cancer Med. 5:2825–2831. DOI:
10.1002/cam4.921. PMID:
27671746. PMCID:
PMC5083735.
Article
6. Merkow RP, Bilimoria KY, Tomlinson JS, Paruch JL, Fleming JB, Talamonti MS, et al. 2014; Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 260:372–377. DOI:
10.1097/SLA.0000000000000378. PMID:
24374509.
Article
8. Pan L, Fang J, Tong C, Chen M, Zhang B, Juengpanich S, et al. 2019; Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis. World J Surg Oncol. 18:1. DOI:
10.1186/s12957-019-1767-5. PMID:
31892339. PMCID:
PMC6937851.
Article
9. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. 2009; The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 339:b2700. DOI:
10.1136/bmj.b2700. PMID:
19622552. PMCID:
PMC2714672.
Article
10. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. 2019. Cochrane handbook for systematic reviews of interventions. 2nd ed. Chichester: John Wiley & Sons.
11. Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C. 2011. User manual for Trial Sequential Analysis (TSA) [Internet]. Copenhagen: Copenhagen Trial Unit, Centre for Clinical Intervention Research;cited 2020 Nov 28. Available from:
https://ctu.dk/tsa/.
12. Schünemann H, Brożek J, Guyatt G, Oxman A. 2013. GRADE handbook for grading quality of evidence and strength of recommendations [Internet]. Available from:
https://www.gradepro.org/. cited 2020 Nov 28. City: The GRADE Working Group.
13. Sobin LH, Gospodarowicz MK, Wittekind C. 2009. TNM classification of malignant tumours. 7th ed. Chichester: Wiley-Blackwell.
14. Tempero MA, Arnoletti JP, Behrman SW, Ben-Josef E, Benson AB 3rd, Casper ES, et al. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2012; 10:703–713. DOI:
10.6004/jnccn.2012.0073. PMID:
22679115. PMCID:
PMC3807091.
16. Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, et al. 2020; Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 38:1763–1773. DOI:
10.1200/JCO.19.02274. PMID:
32105518. PMCID:
PMC8265386.
Article
17. Jang JY, Han Y, Lee H, Kim SW, Kwon W, Lee KH, et al. 2018; Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 268:215–222. DOI:
10.1097/SLA.0000000000002705. PMID:
29462005.
Article
18. Casadei R, Di Marco M, Ricci C, Santini D, Serra C, Calculli L, et al. 2015; Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg. 19:1802–1812. DOI:
10.1007/s11605-015-2890-4. PMID:
26224039.
Article
19. Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, et al. 2015; Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 191:7–16. DOI:
10.1007/s00066-014-0737-7. PMID:
25252602. PMCID:
PMC4289008.
Article
21. Janssen QP, van Dam JL, Bonsing BA, Bos H, Bosscha KP, Coene PPLO, et al. 2021; Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer. 21:300. DOI:
10.1186/s12885-021-08031-z. PMID:
33757440. PMCID:
PMC7989075.
Article